Patents Examined by Andrew B. Freistein
  • Patent number: 7407976
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: August 5, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark T. Miller, Sarah S. Hadida Ruah, Peter D. J. Grootenhuis, Matthew Hamilton
  • Patent number: 7361678
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: April 22, 2008
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Anitha Hari, Kwasi S. Avor, Ghassan Qabaja, Xiao-Chuan Guo, Suparna Gupta, David R. Jones, Xin Chen
  • Patent number: 7342060
    Abstract: A method is disclosed for the production of pentaerythritol diphosphites of high spiro isomer content. The pentaerythritol diphosphites are produced via sequential transesterification of pentaerythritol with a monophosphite followed by a substituted phenol or other alcohol, wherein the transesterification reactions are carried out under controlled conditions of temperature and pressure. The unique reaction conditions result in intermediate and final pentaerythritol diphosphites of high spiro isomer content and high total yield of the diphosphites.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: March 11, 2008
    Assignee: Dover Chemical Corporation
    Inventor: Carroll W. Larke
  • Patent number: 7338968
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: March 4, 2008
    Assignee: Schering Corporation
    Inventors: Purakkattle J. Biju, Arthur G. Taveras, J. Robert Merritt, John J. Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia J. Aki
  • Patent number: 7314875
    Abstract: The present invention provides compounds of the structure: wherein the constituent members are defined herein, including pharmaceutical compositions thereof and methods of treating diseases therewith.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: January 1, 2008
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John A. Gruner, Rabindranath Tripathy
  • Patent number: 7291623
    Abstract: A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: November 6, 2007
    Assignee: Alchemia Limited
    Inventors: Wim Meutermans, Karl Schafer, Michael L. West, Craig Muldoon, Fiona Foley, Natalie Bouloc, Gerald Tometzki
  • Patent number: 7288566
    Abstract: An N-hydroxyformamidine compound of the following formula or a pharmaceutically acceptable salt thereof: wherein R1, A and R are as defined herein. The compounds inhibit 20-HETE-producing enzymes, 20-HETE being involved in the effects of causing microvascular constriction or dilation in major organs (e.g., kidneys, cerebral blood vessels) or of inducing cell proliferation.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: October 30, 2007
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masakazu Sato, Hiroyuki Kakinuma, Hideaki Amada
  • Patent number: 7282590
    Abstract: A compound having the formula Y-A-Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A; Y represents: Z represents: X and E represent O, S, or NRa or NRb; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R1 nor R2 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion; and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemica
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: October 16, 2007
    Assignee: The Research Foundation of State University of New York
    Inventor: Iwao Ojima
  • Patent number: 7282497
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: October 16, 2007
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Patent number: 7282591
    Abstract: The present invention encompasses compounds of Formula I: (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharamaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: October 16, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Amjad Ali, James M. Balkovec, Donald W. Graham, Christopher F. Thompson, Nazia Quraishi
  • Patent number: 7279467
    Abstract: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S.
    Type: Grant
    Filed: December 24, 2002
    Date of Patent: October 9, 2007
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Marie-Odile Galcera Contour, Olivier Lavergne, Marie-Christine Brezak Pannetier, Grégoire Prevost
  • Patent number: 7276518
    Abstract: Substituted cyclohexane-1,4-diamine compounds, methods for production thereof, pharmaceutical compositions comprising these compounds and methods of treatment using these compounds.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: October 2, 2007
    Assignee: Gruenenthal GmbH
    Inventors: Bernd Sundermann, Hagen-Heinrich Hennies, Werner Englberger, Babette-Yvonne Koegel
  • Patent number: 7276539
    Abstract: A compound of formula I wherein R1 represents chloro, fluoro or hydroxy as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: October 2, 2007
    Assignee: AstraZeneca AB
    Inventors: Eva-Lotte Alstermark Lindstedt, Anna Maria Persdotter Boije, Patrick Holm
  • Patent number: 7276602
    Abstract: The invention relates to compounds of the formula 1 or pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof, wherein wherein X, R1, and R2 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: October 2, 2007
    Assignee: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Patent number: 7273879
    Abstract: A thiadiazole compound of the formula (A): wherein R1 represents methyl, C3-C7 alkenyl, C2-C7 alkoxyalkyl, C2-C7 alkylthioalkyl, C4-C7 alkoxyalkoxyalkyl, C4-C7 alkylthioalkoxyalkyl, phenyl C1-C2 alkyl in which phenyl may be substituted, phenyloxy C1-C2 alkyl in which phenyloxy may be substituted, phenyl C2-C3 alkoxyalkyl in which phenyl may be substituted, or the substituent of the formula (B): wherein R3 represents C1-C3 alkyl, and R4 represents a hydrogen atom, methyl, ethyl or phenyl which may be substituted; and R2 represents phenyl C1-C4 alkyl in which phenyl may be substituted, pyridyl C1-C4 alkyl in which pyridyl may be substituted, or pyrimidyl C1-C4 alkyl in which pyrimidyl may be substituted; has an excellent arthropod pests controlling activity.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: September 25, 2007
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Hideki Ihara, Noriyasu Sakamoto, Hiroki Tomioka
  • Patent number: 7271269
    Abstract: Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-hidrox-ymethyl-1-[[2?-(1 H-tetrazole-5-yl)[1.1?-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline potassium salts of 2-n-butyl-5-chloro-5hidroxymethyl-1-[[2?-(1H-tetrazole-5-yl)[1.1?-biphenyl]-44-yl]-1H-imidazole have been prepared.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: September 18, 2007
    Assignee: Lek Pharmaceuticals D.D.
    Inventors: Ljubomir Antoncic, Anton Copar, Peter Svete, Breda Husu-Kovacevic, Zoran Ham, Boris Marolt
  • Patent number: 7271175
    Abstract: In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17?-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17?-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: September 18, 2007
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Yi-Tsung Liu, Ronald J. Doll, Anil Saksena, Viyyoor Girijavallabhan, Jonathan A. Pachter
  • Patent number: 7271178
    Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R11 and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: September 18, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Eli M. Wallace, James Blake
  • Patent number: 7271197
    Abstract: The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: September 18, 2007
    Assignee: Glaxo Group Limited
    Inventors: Philip Charles Box, Diane Mary Coe, Brian Edgar Looker, Panayiotis Alexandrou Procopiou
  • Patent number: 7268156
    Abstract: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: September 11, 2007
    Assignee: SB Pharmco Puerto Rico Inc.
    Inventors: Christopher S. Brook, Wei Chen, Paul G. Spoors